Sorafenib TARGET trial results in Spanish patients
Clin. transl. oncol. (Print)
; 9(10): 671-673, oct. 2007. tab
Artigo
em Inglês
| IBECS
| ID: ibc-123373
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
INTRODUCTION:
Sorafenib improves progression-free survival in advanced clear-cell renal-cell carcinoma patients progressing to first-line therapy, as has been shown in the placebo-controlled international TARGET trial. The aim of this study is to report the results of the patients included in the Spanish centres in this trial. PATIENTS ANDMETHODS:
The records of the patients in the database of the TARGET trial have been reviewed. Data about progression-free survival, overall survival and toxicity have been collected in order to do this subpopulation analysis.RESULTS:
A total of 15 patients have been included (sorafenib arm 7, placebo arm 8). A trend to an improved progression-free survival in the sorafenib arm has been observed period Toxicity in the sorafenib arm has been manageable.CONCLUSION:
The analysis of these 15 patients has shown efficacy and toxicity results that follow the trend observed for the overall international population (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Piridinas
/
Benzenossulfonatos
/
Carcinoma de Células Renais
/
Ensaios Clínicos Controlados Aleatórios como Assunto
/
Ensaios Clínicos Fase III como Assunto
/
Neoplasias Renais
/
Antineoplásicos
Tipo de estudo:
Ensaio clínico controlado
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2007
Tipo de documento:
Artigo
Instituição/País de afiliação:
Farmacéutica Bayer/Spain
/
Hospital Clínico San Carlos/Spain
/
Hospital General Universitari Vall d'Hebrón/Spain
/
Hospital de Cruces/Spain
/
Hospital del Mar/Spain
/
Instituto Valenciano de Oncología/Spain